The IRIS-HIV Assay, a Point-of-Care, Multiplex Serological Assay to Identify HIV Infection and Vaccine-Induced Seropositivity
Award Notice Posted
- Solicitation number
- 75N93022C00030
- Agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Awarded
- to Intuitive Biosciences Inc.
- Set-aside
- Total Small Business
Opportunity facts
- Contract number
- 75N93022C00030 Federal contract award
- Place of performance
- Madison, Wisconsin 53717, United States
Notice details come from SAM.gov. Updated .
About this opportunity
Intuitive Biosciences, Inc. was awarded a $299,855 contract by the National Institute of Allergy and Infectious Diseases to develop a point-of-care, multiplex serological assay called The IRIS-HIV Assay over the next two years. This assay will identify both HIV infection status and immune response to HIV vaccines simultaneously at the point of care. The small business set-aside contract provides funding for Intuitive Biosciences, Inc. to develop this rapid diagnostic test that can be used outside of clinical laboratory settings.
Notice text
Awarded contract 75N93022C00030 to Intuitive Biosciences, Inc. for 299855.00 on 2022-07-01.
Notice history
6 of 8 notices listed here. See the rest on GovTribe.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity